Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00072124
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2003-10-21
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00023738
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
CPG 7909 Injection in Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 184
- Registration Number
- NCT00070642
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00070343
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
- First Posted Date
- 2003-08-28
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 11
- Registration Number
- NCT00005090
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 90
- Registration Number
- NCT00002669
- Locations
- 🇮🇹
Istituto Europeo Di Oncologia, Milano, Italy
🇦🇹Landeskrankenanstalten - Salzburg, Salzburg, Austria
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 482
- Registration Number
- NCT00003027
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 432
- Registration Number
- NCT00006237
- Locations
- 🇺🇸
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00033644
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Tuft-New England Medical Center, Boston, Massachusetts, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 854
- Registration Number
- NCT00003389
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.